Acadian Asset Management
TTNP

Acadian Asset Management’s Titan Pharmaceuticals TTNP Stock Holding History

Acadian Asset Management’s Portfolio TTNP Stock Details TTNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Hold
0
– – – 1850
2023
Q2 		– Hold
0
– – – 1911
2017
Q3 		– Sell
-2
Closed -$17K – 1537
2017
Q2 		$17K Hold
2
– – ﹤0.01% 1278
2017
Q1 		$20K Buy
+2
New +$28.1K ﹤0.01% 1374

Other funds holding TTNP

Truist Financial
Truist Financial Charlotte, North Carolina $74.2B AUM 21.09% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
LFA
Level Financial Advisors East Amherst, New York $448M AUM 16.6% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Acadian Asset Management's TTNP Position: Q3 2023 in Review

Acadian Asset Management held its Titan Pharmaceuticals (TTNP) position steady in Q3 2023 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #1850.

Acadian Asset Management first reported a position in TTNP in Q1 2017 and has held it in 2 quarters since. The position peaked at $20K in Q1 2017. 18 funds tracked by Wall St. Rank hold TTNP as of Q3 2023.

  • Acadian Asset Management held 0 shares of Titan Pharmaceuticals worth $0 as of Q3 2023.
  • Acadian Asset Management left its Titan Pharmaceuticals share count unchanged in Q3 2023.
  • Titan Pharmaceuticals made up ﹤0.01% of Acadian Asset Management's portfolio in Q3 2023, its #1850 holding.
  • Acadian Asset Management first reported a position in Titan Pharmaceuticals in Q1 2017 and has held it in 2 quarters since.
  • Acadian Asset Management's Titan Pharmaceuticals position peaked at $20K in Q1 2017.
  • 18 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q3 2023.

Based on Acadian Asset Management's 13F filing for Q3 2023, filed 13 Nov 2023.